Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone-based first-line regimens for primary immune thrombocytopenia
IRCT20230717058813N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of prednisolone, methylprednisolone and recombinant human thrombopoietin in immune thrombocytopenia (ITP) (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Platelet increase and Corticosteroid adverse effects. Started Oct 2023; status: completed.
02
Drugs
prednisolonemethylprednisolonerecombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on IRCT20230717058813N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230717058813N1.